XERS News and Press, Xeris Pharmaceuticals Inc. From 08/06/19

The following companies have filed prospectuses for mixed shelf offerings: More news on: Neuronetics, Inc., Xenon Pharmaceuticals Inc., Xeris Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

Xeris Pharmaceuticals (NASDAQ: XERS ): Q2 GAAP EPS of -$1.28 misses by $0.32 . More news on: Xeris Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that is has dosed the first subject in a Phase 2 trial with its develop...

Xeris Pharmaceuticals' (NASDAQ: XERS ) ready-to-use glucagon auto-injector showed comparable efficacy with Novo Nordisk's GlucaGen HypoKit for achieving plasma glucose of greater than 70 mg/dl or greater than or equal to 20 mg/dl increase in glucose concentration within 30 minutes of gluco...

Findings will support application for European marketing authorization and augment body of data supporting efficacy and utility of its ready-to-use, stable liquid glucagon Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology pl...

Xeris Pharmaceuticals ( XERS ) shares sold off prior to Gvoke’s PDUFA date on June 10 th . However, the selling pressured subsided dramatically after the company reported that on June 5 th , the FDA extended Gvoke’s PDUFA date by 90 days due to a major amendment to the NDA. An FD...

Noteworthy events during the week of June 9 - 15 for healthcare investors. More news on: Merck & Co., Inc., Xeris Pharmaceuticals, Inc., Mallinckrodt plc, Healthcare stocks news, , Read more ...

The FDA has extended its action date to September 10 for its review of Xeris Pharmaceuticals' (NASDAQ: XERS ) marking application for Gvoke (ready-to-use glucagon injection) for the treatment of severe hypoglycemia (low blood sugar). More news on: Xeris Pharmaceuticals, Inc., Healthcare ...

CHICAGO, June 06, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced today that the U.S. Food a...

Gainers:  La Jolla Pharmaceutical (NASDAQ: LJPC ) +87% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +74% . Ciena Corporation (NYSE: CIEN ) +24% . Cidara Therapeutics (NASDAQ: CDTX ) +21% . Dynatronics Corporation (NASDAQ: DYNT ) +16% . Stitch Fix (NASDAQ: SFIX ) +15% . Eloxx Phar...